Ironwood Pharmaceuticals, Inc.
IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as uā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.85
Price+43.92%
$1.48
1Y
Price
Market Cap
$788.991m
Small
Price/Earnings 3y Avg5y Avg
26.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+63.0%
EBITDA Margin+32.8%
Net Profit Margin+39.0%
Free Cash Flow Margin+63.0%
EBITDA Margin+32.8%
Net Profit Margin+39.0%
Free Cash Flow MarginRevenue
$338.987m
-3.5%
1y CAGR-5.4%
3y CAGR-4.3%
5y CAGREarnings
$28.549m
+3144.2%
1y CAGR+857.3%
3y CAGR+626.2%
5y CAGREPS
$0.15
+1400.0%
1y CAGR+242.8%
3y CAGR+164.6%
5y CAGRBook Value
-$264.157m
$396.062m
Assets$660.219m
Liabilities$598.240m
DebtDebt to Assets
151.1%
4.1x
Debt to EBITDAFree Cash Flow
$67.648m
-34.6%
1y CAGR-37.1%
3y CAGR-26.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company